0001564590-21-010050.txt : 20210302 0001564590-21-010050.hdr.sgml : 20210302 20210302090036 ACCESSION NUMBER: 0001564590-21-010050 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210302 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events FILED AS OF DATE: 20210302 DATE AS OF CHANGE: 20210302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 21701433 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 adpt-8k_20210302.htm 8-K adpt-8k_20210302.htm
false 0001478320 0001478320 2021-03-02 2021-03-02

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2021

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Washington

001-38957

27-0907024

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1551 Eastlake Avenue East, Suite 200,

Seattle, Washington

 

98102

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 7.01.   Regulation FD Disclosure

 

Adaptive Biotechnologies Corporation (the “Company”) and Genentech, Inc. (“Genentech”) are collaborating toward the development of cellular therapy drugs for treating cancer by targeting immune cells to specific shared and personalized cancer-related antigen targets. In response to published data relating to the first shared antigen target candidate, the Company was advised by Genentech on March 1, 2021 that, subject to additional review of certain data, it intends to suspend development of a drug against that shared antigen target. The collaboration will continue to move rapidly toward development of potential drugs against other shared and personal antigen targets already under evaluation. 

 

The Company does not anticipate any material changes to its operating or capital expenses as a result of the suspension of development work to target the first shared antigen candidate, and with respect to revenue guidance, the Company reiterates its full-year 2021 revenue guidance range of $145 million to $155 million.  

Item 8.01.   Other Events

 

The information in the first paragraph of Item 7.01 of this Current Report on Form 8-K (this “Report”) is incorporated by reference into this Item 8.01.

 

This Report contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this Report other than statements of historical fact are forward-looking statements, including express or implied statements regarding the Company’s continued efforts to develop other shared and personalized products for cellular therapy in oncology, continued scaling of research and development efforts, anticipated costs, revenue guidance and related matters, as well as the ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "anticipate," "believe," "continue," "expect," "may," "plan," "project," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this Report represent our views as of the date hereof. The Company undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, with the exception of the information in Item 8.01 above, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Adaptive Biotechnologies Corporation

 

 

 

 

Date: March 2, 2021

 

By:

/s/ Chad Cohen

 

 

 

Chad Cohen

 

 

 

Chief Financial Officer

 

 

 

 EX-101.SCH 2 adpt-20210302.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 adpt-20210302_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 4 adpt-20210302_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 adpt-8k_20210302_htm.xml IDEA: XBRL DOCUMENT 0001478320 2021-03-02 2021-03-02 false 0001478320 8-K 2021-03-02 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 001-38957 27-0907024 1551 Eastlake Avenue East Suite 200 Seattle WA 98102 (206) 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Mar. 02, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 02, 2021
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key 0001478320
Entity Emerging Growth Company false
Entity File Number 001-38957
Entity Incorporation, State or Country Code WA
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1551 Eastlake Avenue East
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98102
City Area Code (206)
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adpt-8k_20210302.htm adpt-20210302.xsd adpt-20210302_lab.xml adpt-20210302_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adpt-8k_20210302.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "adpt-8k_20210302.htm" ] }, "labelLink": { "local": [ "adpt-20210302_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "adpt-20210302_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "adpt-20210302.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20210302", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20210302.htm", "contextRef": "C_0001478320_20210302_20210302", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20210302.htm", "contextRef": "C_0001478320_20210302_20210302", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "verboseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-21-010050-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-010050-xbrl.zip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